Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
19.12B
Market cap19.12B
Price-Earnings ratio
14.99
Price-Earnings ratio14.99
Dividend yield
Dividend yield
Average volume
1.33M
Average volume1.33M
High today
$97.53
High today$97.53
Low today
$95.45
Low today$95.45
Open price
$97.53
Open price$97.53
Volume
1.15M
Volume1.15M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$55.11
52 Week low$55.11

Stock Snapshot

With a market cap of 19.12B, Incyte(INCY) trades at $96.43. The stock has a price-to-earnings ratio of 14.99.

On 2026-04-11, Incyte(INCY) stock moved within a range of $95.45 to $97.53. With shares now at $96.43, the stock is trading +1.0% above its intraday low and -1.1% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.15M, versus its average volume of 1.33M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $55.11.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $55.11.

INCY News

Nasdaq 2d
Incyte Now #415 Largest Company, Surpassing Textron

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Incyte Corporation (Symbol: INCY) has taken over the #4...

Incyte Now #415 Largest Company, Surpassing Textron
TipRanks 4d
Incyte price target raised to $95 from $92 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Incyte (INCY) to $95 from $92 and keeps a Sector Perform rating on the shares as part of th...

Simply Wall St 5d
Incyte Valuation Check As New Povorcitinib Phase 3 Data Draws Investor Interest

Incyte (INCY) is back in focus after releasing 54 week Phase 3 data for its JAK1 inhibitor povorcitinib in moderate to severe hidradenitis suppurativa, alongsid...

Incyte Valuation Check As New Povorcitinib Phase 3 Data Draws Investor Interest

Analyst ratings

52%

of 29 ratings
Buy
37.9%
Hold
51.7%
Sell
10.3%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.